A bowel management intervention for individuals following rectal cancer treatment: assessing feasibility, acceptability and potential effectiveness

Submission date	Recruitment status No longer recruiting	Prospectively registered		
24/05/2011		Protocol		
Registration date 24/05/2011	Overall study status Completed	Statistical analysis plan		
		Results		
Last Edited 29/03/2022	Condition category Cancer	Individual participant data		
		Record updated in last year		

Plain English summary of protocol

http://cancerhelp.cancerresearchuk.org/trials/a-study-looking-at-way-of-helping-people-copewith-bowel-problems-after-treatment-for-rectal-cancer

Contact information

Type(s)

Scientific

Contact name

Dr Claire Taylor

Contact details

Florence Nightingale School of Nursing and Midwifery James Clerk Maxwell Building 57 Waterloo Road London United Kingdom SE1 8WA

gillian.taylor@kcl.ac.uk

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

9931

Study information

Scientific Title

A bowel management intervention for individuals following rectal cancer treatment: assessing feasibility, acceptability and potential effectiveness

Study objectives

A bowel management intervention will be tested upon a cohort of up to 40 patients who have been diagnosed with curative rectal cancer and will be treated by sphincter-saving surgery +/- other cancer treatments. The intervention will have two parts: the first is the delivery of written information and appropriate contact numbers/web-sites and the second is a specific bowel intervention for those with change in bowel habit which consists of one face-to-face appointment and two telephone follow-up calls. Bowel function and quality of life measures will be administered to the sample pre and post these interventions which are orientated to their treatment schedule: pre-treatment, 6 weeks, five months and ten months post-treatment.

Evaluation will be through use of both quantitative and qualitative outcomes including the ICIQ-B Bowel Assessment Instrument (Cotterill et al, 2008), Quality of Life Short Form SF36 and the My Caw tool. There will also be qualitative interviews with members of the cohort who are willing to participate in this additional evaluative feature of the study and a survey of healthcare professionals involved in the follow up care of rectal cancer patients. Assessment of process and other study effects will also be made.

Ethics approval required

Old ethics approval format

Ethics approval(s)

First Medical Ethics Research Committee Ref: 10/H0709/65; approval date 02/11/2010

Study design

Non-randomised, interventional

Primary study design

Interventional

Secondary study design

Non randomised study

Study setting(s)

Hospital

Study type(s)

Quality of life

Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

Health condition(s) or problem(s) studied

Colorectal cancer

Interventions

- 1. Bowel management the planned intervention is based on the current method of Biofeedback therapy offered at St Mark's for patients referred with bowel symptoms of urgency and incontinence
- 2. It will be given by the researcher with support from the Biofeedback team
- 3. To ensure all patients receive consistent pre-operative care, they will all be offered relevant written information about their treatments prior to treatment
- 4. This information provides necessary preparation for what to expect following treatment
- 5. Follow Up Length: 10 months
- 6. Study Entry: Registration only

Intervention Type

Other

Phase

Not Applicable

Primary outcome measure

ICIQ-B; Timepoint(s): pre treatment, 6 weeks post treatment, 5 months, 10 months

Secondary outcome measures

- 1. Bowel assessment and QOL
- 2. Timepoint(s): 1) the ICIQ-B Bowel Assessment Instrument (Cotterill et al, 2008)
- 3. Quality of Life Short Form (SF)

Overall study start date

02/03/2011

Completion date

30/03/2012

Eligibility

Key inclusion criteria

- 1. Diagnosis of curative rectal cancer
- 2. Consents to sphincter saving surgery
- 3. Over 18
- 4. Able to speak and read English
- 5. Patients having pre-op radiotherapy (RT) will be included which may be a short or long course of treatment. Occasionally the RT will be so effective that surgery will not be required can still be included.
- 6. Patients may also have post-operative radiotherapy and chemotherapy treatments 7. Male & Female
- 8. Lower Age Limit 18 years

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Sex

Both

Target number of participants

UK Sample Size: 40

Total final enrolment

28

Key exclusion criteria

- 1. Unable to articulate their diagnosis of cancer due to denial, confusion, learning disability
- 2. Local excision surgery
- 3. Surgery involving formation of permanent stoma
- 4. Under 18
- 5. Unable to read study measures and/or has a level of spoken English which requires a translator.
- 6. Patients who do not want to participate in the intervention

Date of first enrolment

02/03/2011

Date of final enrolment

30/03/2012

Locations

Countries of recruitment

England

United Kingdom

Study participating centre

Florence Nightingale School of Nursing and Midwifery

London United Kingdom SE1 8WA

Sponsor information

Organisation

North London Cancer Research Network (UK)

Sponsor details

Stephenson House 158-160 North Gower Street London United Kingdom NW1 2ND

Sponsor type

Research organisation

Website

http://www.nlcn.nhs.uk/

Funder(s)

Funder type

Research organisation

Funder Name

National Cancer Survivorship Initiative (UK)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

Not provided at time of registration

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Plain English results	in English results	20/05/2016	29/03/2022	No	Yes